Regeneron first-quarter profit more than doubles
May 5 (Reuters) - Regeneron Pharmaceuticals Inc's quarterly profit more than doubled as sales of blockbuster eye drug Eylea jumped 44 percent.
The company's net income rose to $165.7 million, or $1.45 per share, in the first quarter ended March 31, from $76 million, or 66 cents per share, a year earlier.
Revenue rose to $1.2 billion from $869.6 million.
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Saumyadeb Chakrabarty)